Panobinostat PK/PD profile in combination with bortezomib and dexamethasone in patients with relapsed and relapsed/refractory multiple myeloma.
Mu S et al. Eur J Clin Pharmacol. 2015 Oct 22. [Epub ahead of print].

Panobinostat for the treatment of multiple myeloma: the evidence to date.
Bailey H et al. J Blood Med. 2015 Oct 8;6:269-76. doi: 10.2147/JBM.S69140. eCollection 2015.

Panobinostat for the treatment of relapsed or relapsed/refractory multiple myeloma: pharmacology and clinical outcomes.
Richardson PG et al. Expert Rev Clin Pharmacol. 2015 Oct 26:1-14. [Epub ahead of print].

Strategy for enhancing the therapeutic efficacy of histone deacetylase inhibitor dacinostat: the novel paradigm to tackle monotonous cancer chemoresistance.
Ganai SA. Arch Pharm Res. 2015 Oct 19. [Epub ahead of print].

Re-challenging with anti-CD38 monotherapy in triple-refractory multiple myeloma patients is a feasible and safe approach.
Alici E et al. Br J Haematol. 2015 Oct 12. doi: 10.1111/bjh.13776. [Epub ahead of print]